Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065728 · ClinicalTrials.gov registry record · Phase 3
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT00065728 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 111 participants.
The verdict
NCT00065728, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
Interventions
- DRUG Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065728
The ClinicalTrials.gov registry entry for NCT00065728 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL is the first listed.
NCT00065728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065728 about?
NCT00065728 is a clinical study titled "Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD". The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
What is the current status of trial NCT00065728?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2003-06. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00065728?
The interventions under investigation include: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00065728?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.